-Experienced Chief Medical Officer to advance ISA´s clinical pipeline
Leiden, The Netherlands, April 30, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the appointment of Leon Hooftman, MD, to the position of Chief Medical Officer (CMO), effective May 1, 2018. He brings many years of experience in drug development and academic research and has a strong track record in early- and late-stage clinical development with specific expertise in immuno-oncology.
“As we are planning to start two new clinical programs with ISA101b together with Regeneron as well as other clinical
Leiden, The Netherlands, April 26, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the start of a Phase II combination trial of its lead compound ISA101b and Pfizer´s 4-1BB agonist Utomilumab, which will be sponsored and conducted by The University of Texas MD Anderson Cancer Center (Houston, TX).
The goal of the open-label Phase II study in patients with HPV16-positive, incurable oropharyngeal cancer is to investigate whether a combination of ISA101b with Utomilumab is able to shrink or slow the growth of tumors. The safety of the